Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bayer_AG
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:focusesOn |
regenerative medicine
gene therapy |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Emile_Nuwaysir
gptkb:Lorenz_Studer gptkb:Sally_Temple |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
BlueRock Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:BRT-DA01
cell-based therapies for Parkinson's disease |
| gptkbp:operatesIn |
gptkb:Canada
gptkb:United_States |
| gptkbp:parentCompany |
gptkb:Bayer_AG
|
| gptkbp:researchInterest |
cardiology
immunology neurology |
| gptkbp:website |
https://bluerocktx.com
|
| gptkbp:bfsParent |
gptkb:Leaps_by_Bayer
|
| gptkbp:bfsLayer |
6
|